Insights PreviousNextSubscribe to HTA QuarterlyGet at-a-glance updates on important HTA decisions. Each edition of the HTA Quarterly provides insight into the evolving perspectives and priorities for HTAs.Read MoreSubscribe to Health Policy WeeklyRecaps legislative and regulatory developments and healthcare reform news that impacts the healthcare industry.Read More1 of 0 Items ICD-10: A Top Worry on Providers' MindsThe implementation of ICD-10 will introduce thousands of new codes into the healthcare process, putting a significant administrative burden on providers and their office staff. What key issues are weighing on the minds of these stakeholders when it comes to ICD-10? And how will that affect your strategy to prepare your products for the transition? We delved into the question and found some revealing answers. MoreICD-10 Readiness for ManufacturersThe transition to ICD-10 poses many potential challenges for manufacturers. Our most current White Paper provides guidance to become business ready for ICD-10. Discover actionable strategies to offer providers the support programs and tools that will help your patients continue to quickly start, and remain, on therapy. MoreBiosimilars in the US: Are We There Yet?January 7, 2015 marked a historical date for the US healthcare market when the Food and Drug Administration’s (FDA’s) first Oncology Drug Advisory Committee (ODAC) meeting for a biosimilar took place. The drug under review was Sandoz’s biosimilar to filgrastim, still known as EP2006. Dr. Fernandez-Lopez reviews the outcomes and learnings from the meeting and provide insight on what manufacturers need to consider in regard to biosimilars. MoreSmall Population, Huge Impact: Navigating European Market Access With an Orphan Disease ProductDeriving its name from the belief that no manufacturer would care to adopt them, “orphan disease” molecule development was traditionally eschewed by companies for the chance to develop medicines in larger and more profitable markets. Due to the significant incentives available for rare conditions, more and more manufacturers are focusing on developing and marketing molecules for orphan conditions. This article will help you navigate the EMA for sucessful market access. MoreTry Out the HTA Decision MapXcenda's Decision Map makes it easy to stay informed on key HTA decisions from Australia, Canada, France, Germany, and the United Kingdom. MoreHTA Quarterly Archive: Insights to Bridge Science and PolicyFind articles from current and past issues of the HTA Quarterly, Xcenda's e-newsletter written specifically by and for health economics and market access professionals. MoreHealth Policy Weekly ArchiveMiss a recent issue? Get up to date with the latest regulatory and legislative happenings and news that impact stakeholders in the healthcare industry. More Explore More InsightsWe invite you to explore our library of articles, webcasts, white papers, and more.